The carcinogenic effects of di(2-ethylhexyl) phthalate (DEHP), including its potential as an initiator and as a promoter of carcinogenesis, were studied in mouse liver and skin and in rat liver in vivo, and in mouse epidermis-derived JB6 cells in vitro. A mouse model for liver initiation and promotion involved initiation by injection ofN-nitrosodiethylamine (DEN) intraperitoneally into male B6C3F1 mice at 4 weeks of age, followed by exposure to either DEHP in the diet (3000, 6000, or 12,000 ppm) or phenobarbital in the drinking water (500 ppm), beginning 1 to 2 weeks later and continuing for periods of from 1 day to 18 months. Female F344/ NCr rats were subjected to a similar protocol in which promotion continued for 14 weeks. DEHP promoted focal hepatocellular proliferative lesions (FHPL), including hyperplastic foci and neoplasms initiated by DEN in mice but not in rats. Skin-painting studies in female CD-1 or SENCAR mice involved initiation by a single topical exposure to 7,12-dimethylbenz[aI-anthracene (DMBA) applied to the dorsal skin, followed by repeated percutaneous exposure to a tumor promoter, either DEHP or 12-O-tetradecanoylphorbol-13-acetate (TPA). To test for two-stage skin tumor promotion, SENCAR mice were initiated with DMBA and then TPA was administered for only 2 weeks, after which DEHP was subsequently administered for 26 weeks. DEHP displayed very weak complete promoting activity and definite second stage promoting activity in SENCAR mouse skin, but was inactive under our conditions on CD-1 mouse skin. In vitro promoting activity of DEHP and its hydrolysis products, mono(2-ethylhexyl) phthalate (MEHP) and 2-ethylhexanol (EH), was studied by using promotable mouse epidermis-derived JB6 cells. DEHP and MEHP promoted JB6 cells to anchorage independence, while EH did not.
Introduction
Di(2-ethylhexyl) phthalate (DEHP), a plasticizer and hepatic peroxisome proliferator (1) (2) (3) , was found to be carcinogenic in U.S. National Toxicology Program carcinogenesis bioassays (4) , in which it increased the incidence of hepatocellular neoplasms in F344 rats and in B6C3F1 mice. Because DEHP was demonstrated to have no genotoxic activity in bacterial mutagenesis assays or in other in vitro assays (4, 5) , the hypothesis was tenable that this compound achieved its biologic effects by acting as a tumor promoter, enhancing the development of naturally occurring or chemically induced hepatocellular tumors of rats or mice. We have used an in vivo model for liver tumor initiation and promotion in mice that utilizes N-nitrosodiethylamine (DEN) as an initiator in weanling B6C3F1 males (6, 7) , and have adapted the same protocol to weanling female F344 rats. With these systems, we have tested DEHP as a potential initiator of and promoter for hepatocellular tumors in vivo. At least in the mouse skin system, the promotion stage has empirically been subdivided into two distinct components, stage I and stage II, which are qualitatively different from initiation and from each other (8) (9) (10) . Mezerein is only a weak complete promoter, but when given repeatedly (two times per week) after limited exposure to TPA, it induces a significant tumor response in a dosedependent manner (9) . To investigate whether DEHP acts as a tumor initiator or as a complete or second-stage tumor promoter in mouse skin, we used an in vivo assay utilizing CD-1 and SENCAR mice. There are few in vitro assays for tumor promoters, and only one that is predictive of target cell specificity in vivo. This, one of the best characterized cell culture assays, was originally developed to study phorbol esters, and is based on induction by certain substances of transformation of mouse epidermis-derived JB6 cell lines to a neoplastic phenotype, characterized by anchorage inde-pendence and tumorigenicity (11) . Using this system, we tested the promoting abilities of DEHP and its major hydrolysis products, mono (2-ethylhexyl) phthalate (MEHP) and 2-ethylhexanol (EH) .
We report that DEHP promotes but appears not to initiate neoplasia in mouse hepatocytes and mouse skin in vivo and promotes transformation ofJB6 cells in vitro, and that MEHP but not EH promotes JB6 cells in vitro.
Materials and Methods

Chemicals
The following chemicals were purchased: DEN (Sigma Chemical Co., St. Louis, MO, USA), DEHP (Aldrich Chemical Co., Milwaukee, WI, USA), EH (Aldrich Chemical Co., Milwaukee, WI, USA), dimethylbenzanthracene (DMBA) (Eastman Kodak Co., Rochester, NY), and TPA (C.C.R. Inc., Eden Prarie, MN). DEHP was analyzed by GLC by Dr. Gary Muschik (Program Resources Inc., FCRF, Frederick, MD, USA) and found to be 99% pure. MEHP was synthesized by a slight modification of the method described by Kenyon and Platt (12) , and was analyzed by FID/GLC and found to be 96% pure. For in vitro assays, DEHP was mixed with acetone, while MEHP and EH were dissolved in DMSO.
Tumor Initiation, Promotion, and Carcinogenicity in Mouse Liver An initiation-promotion system for male B6C3F1 mouse liver previously described by us was used (6) In a more recent experiment, DEHP was fed in the diet at 3000 ppm, or PB was given in the water at 500 ppm for 1, 7, 28, 84, or 168 days, beginning one week after DEN injection at 4 weeks of age (7) . All mice were killed at 168 days. Additional groups received DEHP or PB for 168 days and were killed 84 days later to observe possible regression of hepatic proliferative lesions.
Pathology
A complete necropsy was performed on all mice. The liver was weighed and examined carefully for gross lesions. Two representative sections were prepared from each lobe (eight sections per mouse) and fixed in formalin for computerized image analysis of hepatic lesions. Focal hepatocellular proliferative lesions (FHPL) included hyperplastic foci, adenomas, and carcinomas and were classified by staining properties to distinguish those that had clear or eosinophilic cytoplasm from those with basophilic cytoplasm (6, 13) . Avidin-biotin peroxidase complex immunocytochemistry was used to localize mouse a-fetoprotein to hepatocytes (6) . The mean number of FHPL per square or cubic centimeters of liver, and mean areas and volumes of FHPL were determined using an automated system (Videoplan, Zeiss, Inc., New York, NY) and Zeiss stereology software. Appropriate statistical analyses were performed (6) . Portions of 23 liver nodules were transplanted to the mammary fat pad of weanling male B6C3F1 mice. Quantitative electron microscopic analysis for cytoplasmic peroxisomes, mitochondria, and rough and smooth endoplasmic reticulum, cell and nuclear cross-sectional areas and nuclear/cytoplasmic ratios were performed on representative liver samples fixed in cold glutaraldehyde from normal untreated mice and from mice treated with DEHP or PB, and on liver tumors in mice given DEN followed by DEHP or PB (14 Fig. 4) . The FHPL in DEN-initiated mice that received DEHP at 12,000 ppm were significantly larger in mean focus volume at 6 months than those of mice in other groups (Fig. 4) . Histologically, these FHPL had increased cell size and more numerous mitotic figures and appeared more potentially malignant than those in mice of other groups, especially the group that received DEN alone (Figs. 5-7) . Hepatocellular carcinomas arose within adenomas (Fig. 8) and replaced much of the liver (Fig. 9) . By 18 months, 25% of the mice given 6000 ppm while those promoted by PB were composed of eosinophilic hepatocytes ( Fig. 11 ) and had abundant cytoplasmic smooth endoplasmic reticulum (Fig. 3b) mice; neither of these neoplasms were significantly affected by DEHP or PB (Table 4) .
Liver Tumor Promotion in F344/NCr Rats
Both standard hematoxylin/eosin histology and histochemical staining for gamma glutamyl transpeptidase were used to identify FHPL in liver sections from DENinitiated rats. DEHP failed to increase the number or size of FHPL detected by either method in rat liver after 16 weeks, while PB was significantly effective at the same doses used in mice (Fig. 13) . Liver weights were higher (6% of body weight) in rats that received DEHP than in controls (3.9%). The FHPL in DEN and DEN-DEHP rats were morphologically similar and composed of clear cells, while those that received PB were composed of hepatocytes with eosinophilic, clear and/or vacuolated cytoplasm. Hepatocytes in livers of rats treated with DEHP were enlarged and contained prominent eosinophilic cytoplasm, evidence of peroxisomal proliferation. Renal lesions were not seen in rats.
Skin Tumor Promotion in Mice
DEHP did not promote the development of skin tumors after DMBA initiation in CD-1 mice ( an initiator or complete skin carcinogen after 40 weeks (15) . In female SENCAR mice, however, DEHP was a weak second-stage promoter and a weaker complete promoter of skin carcinogenesis (Fig. 14) (15) . Mezerein was a considerably stronger second-stage promoter.
Anchorage Independence Induced in Mouse JB6 Cells DEHP showed activity for promotion of transformation in three promotable (p +) JB6 clonal lines of mouse epidermis-derived cells (Table 6 ) (15) . These lines of JB6 cells, including C141, Cl21, and R219, have previously been shown to be promoted by anchorage independence and tumorigenicity by tumor promoting phorbol esters, and also by mezerein, benzoyl peroxide and epidermal growth factor (11) . Of the three cell lines used, Cl41 showed the (4) .
The possible mechanism(s) of tumor promotion by DEHP is (are) unknown. It has been suggested that peroxisome proliferators as a group may be carcinogenic by a nongenotoxic mechanism (3, 16) . The inhibition of hepatic tumorigenesis by the antioxidants ethoxyquin and 2(3)-tert-butyl-4-hydroxyanisole (17) and other recent studies have provided some evidence for the role of free oxygen radicals and lipid peroxidation in carcinogenesis by these compounds. Recent work, however, suggests that this mechanism does not apply to DEHP (5) .
Tumor promotion may result from effects on cellular membranes and/or stimulation of proliferation of cells, including hepatocytes, after exposure to an initiating dose of carcinogen. DEHP has been shown by us and others to produce hepatomegaly, in part due to liver cell (6) . DEHP promoted basophilic FHPL that appeared to grow faster and/or appear sooner in the experiment in mice given the highest dose of DEHP Basophilic adenomas developed from these foci and trabecular carcinomas appeared within the adenomas. The carcinomas metastaszized to the lungs in 10 to 25% of the mice. In contrast, eosinophilic FHPL developed in mice receiving PB after DEN. These foci enlarged slowly to form adenomas and finally carcinomas, some of which metastasized to the lungs. As noted previously, the promoter may have affected directly the morphology and WITH FHPL biology of tumor cells in induced tumors (6) . The evidence for this included the early appearance of basophilic and clear-cell FHPL which resembled those in mice given DEN alone. After these typical foci appeared, DEHP seemed to affect the morphology and mitotic rate of the cells in the FHPL. It is suggested that DEHP increased replication of initiated hepatocytes that appeared morphologically normal and hepatocytes in FHPL that were already morphologically hyperplastic. Thus, the mitogenic effect of DEHP may play an important role in liver tumor promotion (3, 24) . The lack of similar effects on rat liver foci initiated by DEN remains unexplained. It is also possible that DEHP or PB promoted different initiated cell populations in mouse liver, and that as a consequence the morphological and biological properties of FHPL varied for these two liver promoters.
Tumor promotion has been defined by many authors as a reversible process caused by chronic exposure to certain agents, chemicals which are not genotoxic carcinogens but which enhance the appearance, 'growth, and development of initiated cells or tumors (8) (9) (10) . These processes have been best described in skin and liver. More recent studies have shown that reversibility, in part, depends on the specific chemical and on the duration of exposure. Quantitative estimation of tumors or preneoplastic lesions in mice given initiators or promoters also varies with the dosage given and on the time of sacrifice, and depends on the method of evaluation (Table 7 and Fig. 15 ). Our recent studies with DEHP provide additional evidence that tumor promotion can be irreversible if exposure time is sufficient. Although classical promoters, themselves, lack genotoxic activity and strong carcinogenic potential, they almost always cause an increased incidence of tumors in a target organ of toxicity PB and DEHP caused increased incidences of focal hepatocellular proliferative lesions including neoplasms in chronic studies that continued up to 2 years and in which chronic nonneoplastic hepatotoxicity was marked (4) .
Additional studies are in process in our laboratory on the mechanism of tumor promotion by DEHP 
